Amgen to discontinue discounts on anemia drug: report (Reuters)
Reuters – Amgen Inc is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product’s safety, the New York Times said.
More: continued here
Recent Entries
- Rossi takes initiative at Le Mans
- Astronauts make 3rd and final spacewalk of mission (AP)
- Park advocates in cash-poor states seek funding (Reuters)
- Chrysler adds 1,100 jobs at Detroit Jeep plant (AP)
- Intelligence Director Knew His Days Were Numbered
- Car bomb in Shiite town near Baghdad kills 23 (AP)
- Senate financial overhaul could bring change to the boardroom (McClatchy Newspapers)
- UK ‘will push EU on CO2 targets’
- Nas and Marley mix rap and reggae inspired by Africa (Reuters)
- Four-time champ Henin facing tough French Open draw